UVB Light and Sunscreen
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients need vitamin D which is normally produced in the skin in response to ultraviolet light from the sun. Vitamin D is important for calcium absorption and good bone health. Physicians have been using sunscreens to protect patients from skin cancer and the aging effects of sunlight for a least a half a century. Dermatologists have promoted sunscreen use to restrict sunlight exposure especially in white Caucasians. If this behavior is done 100% of the time when outdoors individuals may suffer from vitamin D deficiency. It is impossible to influence persons' behavior to wear sunscreens all the time when outdoors. With the use of sunless tanning agent (DHA), once a week, we can obtain a continuous sunscreen in the top layer of the skin that will not wash off, can't be removed with soap and water, or removed by perspiration. Under these circumstances we can answer the scientific question, will sunscreen use inhibit the production of vitamin D in the skin?
| Condition | Intervention | Phase |
|---|---|---|
|
Vitamin D Status |
Other: Tanning spray Other: UVB |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | 3% Dihydroxyacetone (DHA or Sunless Tanning Agent) Inhibits Vitamin D Production in the Skin in Response to Ultraviolet Light |
- To measure the response of 25(OH)D to 40 milliJoules of UV-B light in white Caucasians with melanoidins-sunscreen from 3% DHA in comparison to the response of control subjects who have not used 3% DHA. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
| Enrollment: | 50 |
| Study Start Date: | May 2008 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tanning spray
To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
|
Other: Tanning spray
using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
|
|
Active Comparator: UVB
To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
|
Other: UVB
receiving 40mJ UV-B phototherapy three times a week for four weeks
|
Eligibility| Ages Eligible for Study: | 19 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- males or females
- ages 19-50 with less than 16 oz milk per day
- less than 10 hours of sun per week
- no Vitamin D supplements
- no anticonvulsants
- no barbiturates
- no steroids
- no meds that increase photosensitivity
- no granulomatous disease
- no liver or kidney disease
- no history of skin cancer
- BMI less than 30
- skin types I & II
Exclusion Criteria:
- None
Contacts and Locations| United States, Nebraska | |
| Creighton University | |
| Omaha, Nebraska, United States, 68131 | |
| Principal Investigator: | Laura A Armas, MD | Creighton University |
More Information
No publications provided
| Responsible Party: | Laura Armas, Creighton University |
| ClinicalTrials.gov Identifier: | NCT00818467 History of Changes |
| Other Study ID Numbers: | Creighton 7 |
| Study First Received: | January 6, 2009 |
| Last Updated: | November 27, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Creighton University:
|
Skin tone Vitamin D |
ClinicalTrials.gov processed this record on May 19, 2013